{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06431776",
            "orgStudyIdInfo": {
                "id": "SAV006-04"
            },
            "organization": {
                "fullName": "Savara Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).",
            "officialTitle": "An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).",
            "therapeuticArea": [
                "Respiratory"
            ],
            "study": "inhaled-molgramostim-in-pediatric-participants-with-autoimmune-pulmonary-alveolar-proteinosis-apap"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-22",
            "studyFirstSubmitQcDate": "2024-05-22",
            "studyFirstPostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Savara Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18. The main questions it aims to answer are:\n\nThe effect of molgramostim on breathing tests and activity in pediatric patients with aPAP and the safety of molgramostim in pediatric patients with aPAP.\n\nThis is an open-label study: all participants will receive treatment with molgramostim.\n\nPatients will:\n\n* Take molgramostim once daily via nebulizer every day for 12 months.\n* Visit the clinic approximately every 12 weeks for checkups and tests.\n* Keep a diary of any oxygen use.",
            "detailedDescription": "This is an interventional open-label, single arm, multi-center study in pediatric subjects, age 6 through 18 years, who are diagnosed with autoimmune pulmonary alveolar proteinosis (aPAP).\n\nThe diagnosis of aPAP should be confirmed by an anti-GM-CSF antibody test and a history compatible with PAP based on patient symptoms, high resolution computed tomography of the lung, lung biopsy or bronchoalveolar lavage cytology.\n\nThe study consists of a 4-week screening period followed by a 48-week open-label treatment period. After completing the 48-week treatment or early withdrawal, subjects will enter a 4-week safety follow up period. The maximum treatment duration is 48-weeks, and the maximum study period will be 56 weeks. During the trial, lung lavage will be allowed as a rescue treatment in case of worsening of aPAP."
        },
        "conditionsModule": {
            "conditions": [
                "Autoimmune Pulmonary Alveolar Proteinosis"
            ],
            "keywords": [
                "alveolar proteinosis",
                "autoimmune",
                "lung lavage",
                "GM-CSF",
                "children"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Open-label study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 5,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "molgramostim",
                    "type": "EXPERIMENTAL",
                    "description": "Molgramostim 300 mcg administered once daily via nebulizer for 48 weeks.",
                    "interventionNames": [
                        "Drug: Molgramostim"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Molgramostim",
                    "description": "Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.",
                    "armGroupLabels": [
                        "molgramostim"
                    ],
                    "otherNames": [
                        "Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)."
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "DLCO",
                    "description": "Change in Hb-adjusted % predicted DLCO from Baseline.",
                    "timeFrame": "24 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "DLCO",
                    "description": "Change in Hb-adjusted % predicted DLCO from Baseline .",
                    "timeFrame": "48-weeks"
                },
                {
                    "measure": "6-minute walk distance",
                    "description": "Absolute change from Baseline in 6-minute walk distance (6MWD)",
                    "timeFrame": "24-weeks"
                },
                {
                    "measure": "6-minute walk distance",
                    "description": "Absolute change from Baseline in 6-minute walk distance (6MWD).",
                    "timeFrame": "48-weeks"
                },
                {
                    "measure": "PedsQL",
                    "description": "Change from Baseline in Pediatric Quality of Life (PedsQLTM) Generic Core Scale score.",
                    "timeFrame": "24-weeks"
                },
                {
                    "measure": "PedsQL",
                    "description": "Change from Baseline in Pediatric Quality of Life (PedsQLTM) Generic Core Scale score.",
                    "timeFrame": "48-weeks"
                },
                {
                    "measure": "Oxygen Saturation (SpO2)",
                    "description": "Absolute change from Baseline in oxygen saturation (SpO2)",
                    "timeFrame": "24 weeks"
                },
                {
                    "measure": "Oxygen Saturation (SpO2)",
                    "description": "Absolute change from Baseline in oxygen saturation (SpO2)",
                    "timeFrame": "48 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Adverse events (AEs), including clinically significant findings on pulmonary function tests and safety laboratory assessments and adverse events of special interest (AESIs; hypersensitivity and chest pain).",
                    "timeFrame": "48 weeks"
                },
                {
                    "measure": "Anti-GM-CSF Ab titer",
                    "description": "Titers of anti-GM-CSF antibodies",
                    "timeFrame": "0, 4, 12,24,48 and 52 weeks"
                },
                {
                    "measure": "FEV1",
                    "description": "Change from Baseline in forced expiratory volume in one second (FEV1) (% predicted)",
                    "timeFrame": "24 and 48-weeks"
                },
                {
                    "measure": "FVC",
                    "description": "Change from Baseline in Forced vital capacity (FVC) (% predicted)",
                    "timeFrame": "24 and 48-weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Be \u22656 and \\<18 years of age, at the time of signing the informed consent and informed assent (if applicable).\n* Have a history of pulmonary alveolar proteinosis, based on examination of a lung biopsy, bronchoalveolar lavage cytology, or a high-resolution computed tomogram of the chest.\n* Have a positive serum anti-GM-CSF autoantibody test result confirming aPAP.\n* Have a hemoglobin (Hb)-adjusted diffusing capacity of the lung for carbon monoxide (DLCO) \u226470% predicted at Screening.\n\nExclusion Criteria:\n\n* Have a diagnosis of hereditary (congenital) or secondary PAP, or a metabolic disorder of surfactant production.\n* Have undergone treatment with Lung Lavage (WLL) within 1 month of Baseline",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Years",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Yasmine Wasfi, MD, PhD,",
                    "role": "CONTACT",
                    "phone": "1 512 851 1364",
                    "email": "yasmine.wasfi@savarapharma.com"
                },
                {
                    "name": "Raymond D Pratt, MD",
                    "role": "CONTACT",
                    "phone": "1 240 899 7058",
                    "email": "ray.pratt@savarapharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Yasmine Wasfi, MD, Ph.D.",
                    "affiliation": "Savara Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cincinnati Children's Hospital Medical Center",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229-3039",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011649",
                    "term": "Pulmonary Alveolar Proteinosis"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M27137",
                    "name": "Respiratory Aspiration",
                    "relevance": "LOW"
                },
                {
                    "id": "M14503",
                    "name": "Pulmonary Alveolar Proteinosis",
                    "asFound": "Pulmonary Alveolar Proteinosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "asFound": "Autoimmune Pulmonary Alveolar Proteinosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T568",
                    "name": "Autoimmune Pulmonary Alveolar Proteinosis",
                    "asFound": "Autoimmune Pulmonary Alveolar Proteinosis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000082430",
                    "term": "Molgramostim"
                },
                {
                    "id": "C000081222",
                    "term": "Sargramostim"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M257633",
                    "name": "Molgramostim",
                    "asFound": "Induced Hypotension",
                    "relevance": "HIGH"
                },
                {
                    "id": "M219218",
                    "name": "Sargramostim",
                    "asFound": "Right lower extremity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}